A patient on dialysis asks why he is receiving aluminum hydroxide gel (Amphojel), a phosphate binder, for his renal disorder. What should the nurse explain regarding the action of that Amphojel?

Choice A rationale Aluminum hydroxide gel is not indicated for stimulating appetite in patients with renal failure. While patients on dialysis often suffer from anorexia due to uremia and metabolic imbalances, the administration of a phosphate binder is specifically targeted at mineral metabolism. Improving appetite in this population usually involves managing uremic toxins through effective dialysis and addressing potential zinc deficiencies or psychological factors, rather than using gastrointestinal medications that primarily function to bind ions within the intestinal lumen. Choice B rationale Although aluminum hydroxide is an antacid that can neutralize gastric acid, its primary therapeutic use in chronic kidney disease is not for treating an upset stomach. Patients with renal failure frequently experience gastrointestinal symptoms like nausea, but the specific timing of aluminum hydroxide administration with meals is intended to optimize its interaction with dietary phosphorus. Using it simply for symptomatic relief of dyspepsia would not address the critical need for phosphate control and the prevention of secondary hyperparathyroidism. Choice C rationale In renal failure, the kidneys cannot adequately excrete phosphorus, leading to hyperphosphatemia. Aluminum hydroxide acts as a phosphate binder in the digestive tract, where it combines with dietary phosphorus to form insoluble aluminum phosphate, which is then excreted in the feces. Normal serum phosphorus ranges from 3.0 to 4.5 mg/dL. By lowering serum phosphorus, the medication helps prevent the reciprocal drop in serum calcium, which normally ranges from 9.0 to 10.5 mg/dL, thereby protecting bone health and preventing calciphylaxis. Choice D rationale Aluminum hydroxide does not function to correct the pH of the bowel in patients with renal disorders. Its biochemical role is centered on ion exchange and the formation of insoluble salts rather than altering the overall acid base balance of the intestinal environment. While it can neutralize hydrochloric acid in the stomach, this effect is secondary to the goal of mineral homeostasis in dialysis patients. Management of bowel pH is not a standard clinical objective for treating the systemic complications of end stage renal disease.